GW Pharmaceuticals to Report Q2 2015 Financial Results and Host Conference Call on 11 May, 2015
May 06 2015 - 7:00AM
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the
Company"), a biopharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from its
proprietary cannabinoid product platform, will announce on 11 May,
2015 its second quarter and half year financial results for the
period ending 31 March, 2015. GW will also host a conference call
the same day at 8:00 a.m. EDT (1:00 p.m. BST).
Conference call information will be provided in the financial
results press release. A replay of the call will also be available
through the Company's website (www.gwpharm.com) shortly after the
call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex®, which is approved for the
treatment of spasticity due to multiple sclerosis in 27 countries
outside the United States. GW is advancing an orphan drug program
in the field of childhood epilepsy with a focus on Epidiolex®,
which is in Phase 3 clinical development for the treatment of
Dravet syndrome and which is also expected to enter Phase 3
clinical trials in the treatment of Lennox-Gastaut syndrome and
Tuberous Sclerosis Complex. GW has a deep pipeline of additional
cannabinoid product candidates which includes Sativex in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer, as well as compounds in Phase 1 and 2 trials
for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia.
For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
(Today) +44 20 3727
1000 |
Stephen Schultz, VP Investor Relations
(U.S.) |
917 280 2424 / 401 500 6570 |
|
|
FTI Consulting (Media
Enquiries) |
|
Ben Atwell / Simon Conway / John Dineen
(UK) |
+ 44 20 3727 1000 |
Robert Stanislaro (U.S.) |
212 850 5657 |
|
|
Trout Group, LLC (U.S. investor
relations) |
|
Todd James / Chad Rubin |
646 378 2900 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2023 to Jul 2024